Research
Hormonal
Maintaining high levels of PGC-1α during catabolic conditions (such as denervation or fasting) prevents muscle loss by inhibiting the transcriptional activity of FoxO3 and NF-κB, thereby blocking protein degradation pathways without affecting protein synthesis.
For those at risk of muscle wasting (e.g., due to illness or inactivity), keeping PGC-1α levels high is protective. This is best achieved through regular exercise, which naturally upregulates PGC-1α. This helps block the signals (FoxO3/NF-κB) that tell your muscles to break down, preserving mass even when you are not eating enough or are stressed.
GoodSupportsHIGH confidence
maintaining PGC-1α levels high during catabolic conditions... spares muscle mass during hind limb suspension, sarcopenia, cardiac cachexia, denervation, fasting, or expression of constitutively active FoxO3... The positive action on muscle mass of these cofactors is caused by the inhibition of the autophagic-lysosomal and the ubiquitin proteasome degradation pathways. PGC-1α and β reduce protein breakdown by inhibiting the transcriptional activity of FoxO3 and NF-κB, but they do not affect protein synthesis
Why this rating
Based on transgenic mouse models and human patient data cited in the review.
Source
Mitochondrial Quality Control and Muscle Mass Maintenance
Vanina Romanello et al. · Frontiers in Physiology · 2016
DOI 10.3389/fphys.2015.00422
narrative_reviewCited 426×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Exercise improves mitochondrial function and muscle mass maintenance by activating mitochondrial biogenesis and mitophagy, counteracting catabolic signaling pathways triggered by dysfunctional mitochondria.Good
- Resistance exercise induces the expression of PGC-1α4, a splice variant that promotes muscle hypertrophy by inducing IGF1 and repressing myostatin, whereas endurance exercise does not significantly induce this variant.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →